Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7360595 | 0.86 | PDCD1 (0.50) | KCNA5L3MBTL1TNFGRM4FFAR1 | |
| SCHEMBL24387800 | 0.84 | KCNA5 (0.52) | KCNA5HTTTNFGRM4FFAR1 | |
| SCHEMBL22076577 | 0.82 | HTT (0.62) | KCNA5HTTL3MBTL1EGLN1 | |
| SCHEMBL7361175 | 0.82 | MMP12 (0.51) | L3MBTL1TNFGRM4FFAR1GPR139 | |
| SCHEMBL13882102 | 0.79 | HIF1A (0.57) | L3MBTL1 | |
| SCHEMBL7363315 | 0.78 | F10 (0.60) | KCNA5FFAR1 | |
| SCHEMBL7686273 | 0.78 | KCNA5 (0.47) | KCNA5HTTTNFFFAR1GPR139 | |
| SCHEMBL8770903 | 0.78 | L3MBTL1 (0.49) | HTTL3MBTL1CNR2 | |
| SCHEMBL8770921 | 0.78 | KCNA5 (0.50) | KCNA5L3MBTL1 | |
| SCHEMBL13482971 | 0.78 | ADRB3 (0.53) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906860-B2 | Method for synthesizing chiral beta-hydroxy acid ester compound | WENZHOU UNIVERSITY (CN) | 2021-02-02 | — | — | US | disclosed |
| US-10906860-B2 | Method for synthesizing chiral beta-hydroxy acid ester compound | WENZHOU UNIVERSITY (CN) | 2021-02-02 | — | — | US | disclosed |
| CN-109734600-B | Synthesis method of chiral beta-hydroxy acid ester compound | 温州大学 | 2020-09-15 | — | — | CN | disclosed |
| US-20200190013-A1 | METHOD FOR SYNTHESIZING CHIRAL BETA-HYDROXY ACID ESTER COMPOUND | WENZHOU UNIVERSITY (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200190013-A1 | METHOD FOR SYNTHESIZING CHIRAL BETA-HYDROXY ACID ESTER COMPOUND | WENZHOU UNIVERSITY (CN) | 2020-06-18 | — | — | US | disclosed |
| CN-109734600-A | A kind of synthetic method of chiral beta carboxylic acid ester type compound | 温州大学 | 2019-05-10 | — | — | CN | disclosed |
| US-6962935-B2 | Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040073029-A1 | Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors | PRUITT JAMES RUSSELL (US) | 2004-04-15 | — | — | US | disclosed |
| US-6569874-B1 | Such as 2-acetylamino-4-(3-amidinophenyl)-5-((2'-amino-sulfonyl-(1,1')-biphen-4 -yl)aminocarbonyl)thiazole; for treatment of thromboembolic disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-27 | — | — | US | disclosed |
| EP-0946528-B1 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6187797-B1 | ANTICOAGULANTS; TRYPSINE-LIKE SERINE PROTEASE INHIBITORS | DUPONT PHARMACEUTICALS COMPANY | 2001-02-13 | — | — | US | disclosed |
| EP-0946528-A2 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028282-A2 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190013-A1 | METHOD FOR SYNTHESIZING CHIRAL BETA-HYDROXY ACID ESTER COMPOUND | HSD11B1, HACL2, HAAO | KCNA5 1361/4885HTT 1595/4885L3MBTL1 3381/4885 |
| US-10906860-B2 | Method for synthesizing chiral beta-hydroxy acid ester compound | HSD11B1, HACL2, HAAO | KCNA5 1361/4885HTT 1595/4885L3MBTL1 3381/4885 |
| US-20040073029-A1 | Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors | F12, XDH, F2 | KCNA5 2661/4885HTT 4455/4885L3MBTL1 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.